IGC Pharma Inc (IGC) Actualités

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

- Interim results indicate cognitive improvement in the active treatment group compared to placebo - No serious adverse events or deaths reported...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

IGC-AD1 demonstrates the potential to modify tau and improve spatial memory Data supports the initiation of clinical trials investigating...

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") announced today that the Company is advancing its proprietary formulation...

IGC Announces Results of its 2024 Annual Stockholders Meeting

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and...

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC-1C Targets Tau Protein and GLP-1 Receptor, Offering a Multi-Pathway Approach to Neurodegenerative and Metabolic Disease Treatment IGC Pharma...

IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

- Artificial Intelligence Modelling Reveals New Possibilities for Metabolic and Neurological Therapies - IGC Pharma, Inc. (NYSE American: IGC...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

IGC Pharma Reports First Quarter Fiscal 2025 Results

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the first fiscal quarter of 2025 ended...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) announces that Alliance Global Partners (AGP) has issued an analyst...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material